Cargando…

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

Detalles Bibliográficos
Autores principales:	Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. P., Jacob, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937881/ https://www.ncbi.nlm.nih.gov/pubmed/29627939 http://dx.doi.org/10.1007/s00415-018-8833-8

Ejemplares similares

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
por: Tallantyre, E. C., et al.
Publicado: (2018)

The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management
por: Patel, Smita Y., et al.
Publicado: (2019)

Clozapine is associated with secondary antibody deficiency
por: Ponsford, Mark, et al.
Publicado: (2019)

A20 deficiency causes spontaneous neuroinflammation in mice
por: Guedes, Renata Padilha, et al.
Publicado: (2014)

Correction: CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation
por: Ruck, Tobias, et al.
Publicado: (2013)

Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination
por: Inaba, Tohru, et al.
Publicado: (2022)

Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data
por: Kareva, Irina, et al.
Publicado: (2021)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Correction: Expression Patterns of Bovine CD1 In Vivo and Assessment of the Specificities of the Anti-Bovine CD1 Antibodies
Publicado: (2015)

Correction: Derivation of Neural Stem Cells from Human Adult Peripheral CD34+ Cells for an Autologous Model of Neuroinflammation
Publicado: (2014)

Editorial: The Complexity of Primary Antibody Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2021)

Correction: Early dysregulation of the memory CD8(+) T cell repertoire leads to compromised immune responses to secondary viral infection in the aged
por: Connor, Lisa M, et al.
Publicado: (2013)

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20(+)CD27(+)CD43(+)CD70(−)
por: Griffin, Daniel O., et al.
Publicado: (2011)

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20(+)CD27(+)CD43(+)CD70(−)
por: Griffin, Daniel O., et al.
Publicado: (2011)

Correction: P-Glycoprotein Acts as an Immunomodulator during Neuroinflammation
por: Kooij, Gijs, et al.
Publicado: (2010)

Correction: Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation
por: Sotnikov, Ilya, et al.
Publicado: (2014)

Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
por: Singh, Vijay, et al.
Publicado: (2014)

Correction: Motor neuron survival is associated with reduced neuroinflammation and increased autophagy after brachial plexus avulsion injury in aldose reductase-deficient mice
por: Zhong, Ke, et al.
Publicado: (2023)

Correction: CD40L Deficiency Attenuates Diet-Induced Adipose Tissue Inflammation by Impairing Immune Cell Accumulation and Production of Pathogenic IgG-Antibodies
por: Wolf, Dennis, et al.
Publicado: (2012)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Correction: New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles
por: Mezzaroba, Nelly, et al.
Publicado: (2013)

Correction to: Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Correction to: the disruption of mitochondrial axonal transport is an early event in neuroinflammation
por: Errea, Oihana, et al.
Publicado: (2017)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Nerve sheath tumours
por: Robertson, James A., et al.
Publicado: (2018)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies
por: Sottini, Alessandra, et al.
Publicado: (2020)

Correction: A20 (Tnfaip3) Deficiency in Myeloid Cells Protects against Influenza A Virus Infection
por: Maelfait, Jonathan, et al.
Publicado: (2012)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011)

Correction: Acetylcholinesterase Inhibitors Reduce Neuroinflammation and -Degeneration in the Cortex and Hippocampus of a Surgery Stress Rat Model
por: Kalb, Alexander, et al.
Publicado: (2013)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion
por: Shultz, Sandy R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e0sbe13vo4g35rh9vgn4a53hjm